NCT03971409
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03971409
Title Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe)
Acronym InCITe
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Laura Huppert, MD, BA
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
O'Neal Comprehensive Cancer Center Birmingham Alabama 35294 United States Details
University of California, San Francisco San Francisco California 94143 United States Details
Georgetown University Washington D.C. District of Columbia 20057 United States Details
University of Chicago Medicine Comprehensive Cancer Center Evergreen Park Illinois 60805 United States Details
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Baltimore Maryland 21218 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
Duke Cancer Institute Durham North Carolina 27710 United States Details
Abramson Cancer Center, University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
Vanderbilt University Ingram Cancer Center Nashville Tennessee 37232 United States Details
Baylor College of Medicine Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field